Tahir Latif

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “COVID-19 vaccination and breakthrough infections in patients with cancer”.

COVID-19 vaccination and breakthrough infections in patients with cancer

Annals of Oncology(2021)10.1016/j.annonc.2021.12.006

N/A

0DataRank · unranked

102 citations

Chris Labaki, Chih–Yuan Hsu, Ziad Bakouny, Nino Balanchivadze, Stephanie Berg +34 more

Momelotinib is a highly potent inhibitor of FLT3-mutant AML

Blood Advances(2021)10.1182/bloodadvances.2021004611

N/A

0DataRank · unranked

19 citations

Zachary Kincaid, Meenu Kesarwani, Arhama Ahmed, Mark Wunderlich, Tahir Latif +3 more

Momelotinib is a highly potent inhibitor of FLT3-mutant AML

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.03.18.436047

N/A

0DataRank · unranked

2 citations

Zachary Kincaid, Meenu Kesarwani, Tahir Latif, Daniel T. Starczynowski, Mohammad Azam +1 more

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML

Blood Advances(2022)10.1182/bloodadvances.2022007486

N/A

0DataRank · unranked

8 citations

Zachary Kincaid, Meenu Kesarwani, Jacob Menke, Joshua Schwieterman, Sekhu Ansari +11 more

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

Nature Medicine(2023)10.1038/s41591-023-02273-z

N/A

0DataRank · unranked

76 citations

Michael P. Rettig, Reyka G. Jayasinghe, Keith Stockerl‐Goldstein, Sarah Larson, Illes Arpad +27 more